论文部分内容阅读
目的探讨乌苯美司联合化疗治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效。方法选取2011年2月至2014年2月间江苏省镇江市丹阳市人民医院收治的104例老年晚期NSCLC患者,采用随机数字表随机分为观察组和对照组,每组52例。两组患者均实施紫杉醇联合顺铂(TP方案)化疗,观察组患者加用乌苯美司口服。比较两组患者近期疗效、不良反应、治疗前后生活质量及免疫功能变化。结果观察组患者有效率(RR)为50.0%,疾病控制率为80.8%,中位无进展生存时间为6.9个月,均显著高于对照组,差异有统计学意义(P<0.05)。观察组患者白细胞减少分级显著低于对照组,差异有统计学意义(P<0.05)。观察组患者KPS评分及身体质量的改善率及稳定率均显著高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后CD3+、CD4+、NK细胞及CD4+/CD8+比值均显著升高,对照组患者治疗后上述指标显著下降,两组比较,差异均有统计学意义(均P<0.05)。结论乌苯美司能够减轻化疗对老年晚期NSCLC患者免疫功能的影响,降低患者白细胞减少等化疗不良反应分级,改善患者生活质量及近期疗效。
Objective To investigate the clinical efficacy of ubenimex combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 104 elderly patients with advanced NSCLC who were admitted to Danyang People’s Hospital of Zhenjiang City, Jiangsu Province from February 2011 to February 2014 were randomly divided into observation group and control group with 52 cases in each group. Two groups of patients were treated with paclitaxel combined with cisplatin (TP regimen) chemotherapy, observation group patients with ubenimex oral. Short-term efficacy, adverse reactions, quality of life before and after treatment, and changes in immune function were compared between the two groups. Results The effective rate (RR) of the observation group was 50.0%, the disease control rate was 80.8%, the median progression-free survival time was 6.9 months, which were significantly higher than that of the control group (P <0.05). The grade of leukopenia in the observation group was significantly lower than that in the control group, the difference was statistically significant (P <0.05). The improvement rate and stability rate of KPS score and body mass in the observation group were significantly higher than those in the control group, the difference was statistically significant (P <0.05). After treatment, the ratio of CD3 +, CD4 +, NK cells and CD4 + / CD8 + were significantly increased in the observation group. The above indexes decreased significantly in the control group after treatment. There were significant differences between the two groups (all P <0.05). Conclusion Ubenimex can reduce the impact of chemotherapy on the immune function of elderly patients with advanced NSCLC, reduce the leukopenia and other chemotherapy adverse reaction grade, improve the quality of life of patients and the short term efficacy.